Subscribe to Search results

With regards to a possible takeover of BPL by Beecham, Peter Wormland of the DHSS stated that was important to reach a decision in principle regarding whether they should reject the commercial option or decide whether they intend to implement it, subject to negations, highlighting issues with further delays to a decision.

Published on:

A review considered various options which included handing over the fractionation process to a commercial industry and concluded that increasing capacity at UK facilities was more viable.

Published on:

B Gidden of the DHSS stated that the arrival of commercial material in quantity precipitated a demand from the NHS which had become more and more insistent, which could not have been anticipated at the time forecast estimates were drawn up a year earlier.

Published on:

A letter from S Murray of the NBTS to Dr Maycock stated that he was quite sure that some clinicians would not be satisfied with halving the amount of cryoprecipitate they were supplied, even if given additional AHG.

Published on:

Malcolm Harris wrote a letter to Ms Westbrook regarding the benefit of transfer pricing to regions. Under the cross-charging system, BPL paid regional transfusion centres a national price for supplying plasma and the regions paid BPL for the blood products supplied.

Published on:

The Central Blood Laboratories Authority's Activity and Current Issues Update Report May 1988 was published.

Published on:

Ian Marshall wrote to Professor Bloom stating that the three high risk groups were excluded from 27 December 1982 but in the press release it gave the date of 20 December 1982.

Published on:

A press release stated Alpha had contacted its "several hundred plasma suppliers" and they "must 'exclude donors' who may be part of three potentially high-risk groups: persons who have been in Haiti: drug abusers and male homosexuals. There is a 'higher incidence of AIDS' in these groups than in the community at large, the company says."

Published on:

Alpha warned on the package insert for Antihaemophilic Factor (Human) dried Profilate Heat-Treated "The causal factors of Acquired Immune Deficiency Syndrome...have no been fully defined. However, HTLV-III/LAV virus has been implicated as a possible agent of the disease."

Published on:

During the licensing process, the licensing authority required references to heat treatment to be that it was intended to "reduce the risk of transmission of infectious agents" rather than making claims about it reducing the risks of HIV or non-A non-B Hepatitis by name.

Published on:

Cutter and the FDA discussed adding an AIDS warning to US product information, leading to the addition of such a warning in December.

Published on:

Cutter and the FDA noted that: "Isolated cases of Acquired Immune Deficiency Syndrome (AIDS) have been reported in hemophilics [sic] who have received blood and/or coagulation factor concentrates, including Factor VIII concentrates."

Published on:

Professor Arthur Bloom maintained to the annual general meeting of haemophilia centre directors there was no proof that commercial concentrates were the cause of AIDS.

Published on:

An AIDS warning was added to US product information in December 1983, however the earliest product warning in the UK which the Inquiry was able to identify was in March 1984.

Published on:

It was widely known that gay men in particular were at risk of developing a failure of the immune system, which was indeed called GRIDS (Gay Related Immunodeficiency Syndrome).

Published on:

Dr Kingdon wrote "Many of us have been involved in considering the problem and in discussions with the CDC on its implication for our blood products."

Published on:

Dr Kingdon recorded "we have been closely monitoring the issue at Hyland".

Published on:

Dr Evatt anticipated that a public meeting to be held at the instigation of the CDC would be a "pro forma stamp for action, that is, review the data, accept the evidence as significantly supporting the case for blood-borne infection and produce recommendations that high-risk groups be excluded from the donor pool and/or adopt a surrogate test."

Published on:

Dr Evatt and his colleagues "were now convinced that in spite of the absence of an identified agent, the pattern of the epidemiological evidence was sufficient to implicate a blood-borne disease."

Published on:

The Committee on Safety of Medicines advised against issuing a product licence for heat-treated Hemofil in September 1983 in part because of the absence of evidence that AIDS was transmitted by a virus and hence might be affected by heat treatment.

Published on: